Provided by Tiger Trade Technology Pte. Ltd.

Biomea Fusion, Inc.

1.32
+0.04003.13%
Post-market: 1.320.00000.00%19:55 EST
Volume:660.14K
Turnover:854.57K
Market Cap:93.33M
PE:-0.60
High:1.33
Open:1.30
Low:1.26
Close:1.28
52wk High:3.75
52wk Low:0.8719
Shares:70.70M
Float Shares:57.24M
Volume Ratio:1.00
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2050
EPS(LYR):-3.8339
ROE:-209.00%
ROA:-75.23%
PB:5.98
PE(LYR):-0.34

Loading ...

Biomea Fusion to Present at Oppenheimer Healthcare Life Sciences Conference

Reuters
·
Yesterday

Biomea Fusion to Participate at Upcoming Investor Conferences

GlobeNewswire
·
Yesterday

Biomea Fusion Highlights Diabetes Pipeline at JPM Conference

TIPRANKS
·
Jan 15

Biomea Fusion initiated with a Buy at Rodman & Renshaw

TIPRANKS
·
Jan 14

Biomea Fusion Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jan 13

Biomea Fusion Inc. Announces 2026 Strategy Focusing on Advancing Icovamenib and BMF-650 Clinical Programs, Initiating Phase II Trials in Type 2 Diabetes and Continuing Oral GLP-1 Candidate Development

Reuters
·
Jan 12

Director and Officer Rainer M. Erdtmann Acquires Common Shares of Biomea Fusion Inc

Reuters
·
Dec 16, 2025

Biomea Fusion Highlights Icovamenib Data at WCIRDC 2025

Reuters
·
Dec 10, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies

Reuters
·
Dec 06, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Warner Bros Discovery, Ulta Beauty, Victoria's Secret

Reuters
·
Dec 05, 2025

BUZZ-Biomea Fusion rises as diabetes drug shows promise

Reuters
·
Dec 05, 2025

Biomea Fusion Reports Durable Glycemic Improvements with Icovamenib in Type 2 Diabetes Trial

Reuters
·
Dec 05, 2025

Biomea Fusion Presents Covalent-111 Study Results at the 23Rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (Wcirdc)

THOMSON REUTERS
·
Dec 05, 2025

Interim CEO Michael J.M. Hitchcock Reports Acquisition of Biomea Fusion Inc. Common Shares

Reuters
·
Dec 05, 2025

Biomea Fusion Inc. CEO and Director Rainer M. Erdtmann Reports Acquisition of Common Shares

Reuters
·
Dec 03, 2025

Biomea Fusion Unveils Positive Long-Term Icovamenib Data in Type 2 Diabetes at WCIRDC

Reuters
·
Dec 02, 2025

Biomea Fusion Announces Oral Presentation of Icovamenib at the 23Rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (Wcirdc)

THOMSON REUTERS
·
Dec 02, 2025

Biomea Fusion Grants Stock Options to New Employee Under 2023 Inducement Plan

Reuters
·
Dec 02, 2025

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Dec 02, 2025

Biomea Fusion to Join Piper Sandler and Evercore Healthcare Investor Conferences

Reuters
·
Nov 24, 2025